An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases

被引：4
|
作者：
Hong, Seung Wook [1 ]
Kim, Yong-Gil [2 ]
Ye, Byong Duk [1 ,3 ]
机构：
[1] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Rheumatol, Coll Med, Seoul, South Korea
[3] Univ Ulsan, Inflammatory Bowel Dis Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 09期
关键词：
ankylosing spondylitis; arthritis; Crohn's disease; CT-P13; efficacy; infliximab; psoriasis; rheumatoid arthritis; safety; spondylitis; ulcerative colitis; ACTIVE RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; CROHNS-DISEASE; BOWEL-DISEASE; INNOVATOR INFLIXIMAB; MAINTENANCE THERAPY; INDUCTION THERAPY; PHASE-III; ANKYLOSING-SPONDYLITIS;
D O I：
10.2217/imt-2020-0086
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed. CT-P13, the first biosimilar of reference IFX, was approved by the European Medicines Agency and licensed by the US FDA for use in all indications of IFX. This updated review summarizes all aspects of CT-P13, including pharmacology and pharmacokinetics, and evaluates its efficacy, safety and immunogenicity for all indications based on the results of the latest clinical trials as well as on real-world experiences.
引用
收藏
页码：609 / 623
页数：15
相关论文
共 50 条
  • [31] Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
    Arguelles-Arias, Federico
    Guerra Veloz, Maria Fernanda
    Perea Amarillo, Raul
    Vilches-Arenas, Angel
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Chaaro Benallal, Dina
    Benitez Roldan, Antonio
    Merino, Vicente
    Ramirez, Gabriel
    Angel Calleja-Hernandez, Miguel
    Caunedo Alvarez, Angel
    Romero-Gomez, Manuel
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (11) : 1290 - 1295
  • [32] Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
    Takeuchi, Tsutomu
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Morita, Akimichi
    Ohtsuki, Mamitaro
    Suzuki, Yasuo
    Watanabe, Mamoru
    Yamanaka, Hisashi
    Hibi, Toshifumi
    DRUG SAFETY, 2023, 46 (10) : 991 - 1005
  • [33] Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
    Keil, Radan
    Wasserbauer, Martin
    Zadorova, Zdena
    Hajer, Jan
    Drastich, Pavel
    Wohl, Pavel
    Benes, Marek
    Bojkova, Martina
    Svoboda, Pavel
    Konecny, Michal
    Falt, Premysl
    Vanasek, Tomas
    Pesta, Martin
    Pesek, Frantisek
    Bouchner, Ludek
    Kozeluhova, Jana
    Novotny, Ales
    Bartuskova, Lucie
    Spicak, Julius
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1062 - 1068
  • [34] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182) : 1671 - 1672
  • [35] Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
    Braun, Juergen
    Kudrin, Alex
    BIOLOGICALS, 2016, 44 (04) : 257 - 266
  • [36] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [37] CT-P13 subcutaneous infliximab in gastroenterology and rheumatology
    Ahmed, Mai
    Bankov, Giulia
    Casey, Dan
    Perry, Martin Edward
    IMMUNOTHERAPY, 2021, 13 (12) : 1001 - 1009
  • [38] Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Kim, Nam Hee
    Lee, Ji Hyun
    Hong, Sung Noh
    Yoon, Hyuk
    Kang, Hyoun Woo
    Lee, Suck-Ho
    Im, Jong Pil
    Cha, Jae Myung
    Eun, Chang Soo
    Kim, Ji Won
    Choi, Chang Hwan
    Park, Dong Il
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (09) : 1523 - 1532
  • [39] Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
    Jae Hee Cheon
    Seongsu Nah
    Hyoun Woo Kang
    Yun Jeong Lim
    Sang-Hoon Lee
    Sang Joon Lee
    Sung Hyun Kim
    Na Hyun Jung
    Jeong Eun Park
    Yeo Jin Lee
    Da Bee Jeon
    Yeon Mi Lee
    Jong Min Kim
    Sung-Hwan Park
    Advances in Therapy, 2021, 38 : 4366 - 4387
  • [40] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Nakagawa, Tomoo
    Kobayashi, Taku
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Asai, Satoshi
    Sameshima, Yulcinori
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2019, 17 (04) : 504 - 515
12345